EEF1E1 and neoplasm: Our study, on the other hand, demonstrates the loss of AIMP3 in tumours as a beneficial factor for DNA-damaging anticancer treatments, insinuating that AIMP3 itself as a potential target against the genomic integrity of cancer cells.